Remedent Reports Fiscal First Quarter 2010 Results

DEURLE, BELGIUM and LOS ANGELES, CA--(Marketwire - August 14, 2009) - Remedent, Inc. (OTCBB: REMI), an international company specializing in the research, development,
and manufacturing of oral care and cosmetic dentistry products, reported
results for the fiscal first quarter ended June 30, 2009 (in U.S. dollars).

Net sales in the first quarter totaled $2.2 million, a decrease of 41% from
$3.6 million in the same year-ago quarter. The decrease in revenue is
attributed to delays in establishing a new, state-of-the-art manufacturing
and production facility in Beijing, China, which in turn resulted in delays
in fulfilling certain orders from the company's international distributors.
The new facility is designed to address increasing demand and improve gross
margins, while sustaining the high quality of GlamSmile dental veneers.
Management expects the new facility will be in full operation by the third
fiscal quarter.

Loss from operations in the first quarter was $529,000, as compared to
income from operations of $348,000 in the same year-ago quarter, and was
attributable to the decrease in year-over-year net sales.

Net loss for the first quarter totaled $549,000 or $(0.03) per share (after
minority interest and based on 20.0 million weighted average basic shares
outstanding), as compared to income of $331,000 or $0.02 per share (based
on 18.6 million weighted average basic shares outstanding) in the same
year-ago quarter.

Net comprehensive loss in the first quarter after foreign currency
translation adjustment was $492,000 or $(0.02) per share, compared to net
comprehensive income of $358,000 or $0.02 per share in the same year-ago
quarter.

Cash and cash equivalents totaled $1.6 million at June 30, 2009, a decrease
of 12% from $1.8 million at March 31, 2009.

Management Commentary

"This first quarter of our fiscal year represents a transitional quarter as
we took more control over our future by establishing a new worldwide
production facility in China," said Guy De Vreese, CEO of Remedent. "Our
goal was to prepare for increasing demand and improve margins, but still
maintain or even improve the quality of our dental veneers. We achieved
this during the quarter, and are now able to deliver veneers at exceptional
thinness and durability which are second to none in the industry. However,
delays in ramping up production resulted in loss or delays in shipping
international orders during the quarter. We are now effectively bringing
this new facility up to speed and we expect to be producing timely
shipments at higher capacity by the third fiscal quarter.

"During the first quarter, we were also focused on advancing the
development and market introduction of our revolutionary, patent-pending
FirstFitT system for crowns and bridges, which we announced to the world
in June. Our FirstFit development effort culminated with the expansion of
our distribution agreement with Den-Mat Holdings to include FirstFit. As
the world's largest producer of dental veneers, Den-Mat's complete adoption
of our GlamSmile technology in August of 2008 has solidified our position
as a world leader in the dental veneer space. Den-Mat will now champion the
market introduction of FirstFit in the United States through their network
of more than 10,000 dentists.

"As I mentioned last quarter, we are beginning to emerge from a pivotal
stage in our development, with a new operational structure designed to
leverage the proven potential of our unique veneer technology. In addition
to Den-Mat in the United States, we are also realizing increasing demand
from our markets in China and Australia. We are also finding ways to reduce
our costs and improve margins, like our new 'in-house' production facility,
while preparing for strong growth. We believe our wide-ranging progress
throughout the year, while at times facing setbacks, has kept us on course
for continued market expansion in fiscal 2010."

Teleconference Information

Remedent will host a conference call on Friday, August 14, 2009 at 9:00
a.m. Eastern time to discuss these results. A question and answer session
will follow management's presentation. To participate in the call, dial the
appropriate number 5-10 minutes prior to the start time, request the
Remedent conference call and provide the conference ID.

Date: Friday, August 14, 2009
Time: 9:00 a.m. Eastern time (6:00 a.m. Pacific time)
Dial-In Number: 1-800-862-9098
International: 1-785-424-1051
Conference ID#: 7REMEDENT

A simultaneous webcast and replay of the call will be accessible via this
link: http://viavid.net/dce.aspx?sid=000068A3.

Please call the conference telephone number 5-10 minutes prior to the start
time. An operator will register your name and organization and ask you to
wait until the call begins. If you have any difficulty connecting with the
conference call, please contact the Liolios Group at 1-949-574-3860.

A telephone replay of the call will be available from 12:00 p.m. Eastern
time on the same day until September 14, 2009.

Toll-free replay number: 1-800-727-6189
International replay number: 1-402-220-2671
(No passcode required)

About Remedent

Remedent, Inc. specializes in the research, development, manufacturing and
marketing of oral care and cosmetic dentistry products. The company serves
professional dental industry with breakthrough technology for dental
veneers, bridges and crowns that are recognized worldwide for their
technological superiority and ease-of-application. These products are
supported by a line of professional veneer whitening and teeth sensitivity
solutions. Headquartered in Belgium, Remedent distributes its products to
more than 35 countries worldwide. For more information, go to
www.remedent.com.

Statement under the Private Securities Litigation Reform Act of
1995

Statements in this press release that are "forward-looking statements" are
based on current expectations and assumptions that are subject to risks and
uncertainties. Such forward-looking statements involve known and unknown
risks, uncertainties and other unknown factors that could cause Remedent's
actual operating results to be materially different from any historical
results or from any future results expressed or implied by such
forward-looking statements. In addition to statements that explicitly
describe these risks and uncertainties, readers are urged to consider
statements that contain terms such as "believes," "belief," "expects,"
"expect," "intends," "intend," "anticipate," "anticipates," "plans,"
"plan," "projects," "project," to be uncertain and forward-looking. Actual
results could differ materially because of factors such as Remedent's
ability to achieve the synergies and value creation contemplated by our
distribution and licensing agreements. For further information regarding
risks and uncertainties associated with Remedent's business, please refer
to the risk factors described in Remedent's filings with the Securities and
Exchange Commission, including, but not limited to, its annual report on
Form 10-K and quarterly reports on Form 10-Q.

REMEDENT, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

June 30, March 31,
2009 2009
------------ ------------
ASSETS (unaudited)
CURRENT ASSETS:

Cash and cash equivalents $ 1,598,294 $ 1,807,271

Accounts receivable, net of allowance for
doubtful accounts of $36,188 at June 30, 2009
and $33,966 at March 31, 2009 3,373,343 3,208,120

Inventories, net 2,056,141 1,937,946

Prepaid expense 1,321,700 1,310,900
------------ ------------

Total current assets 8,349,478 8,264,237
------------ ------------

PROPERTY AND EQUIPMENT, NET 1,001,394 1,024,999

OTHER ASSETS

Long term investments and advances 750,000 750,000

Patents, net 75,092 163,106
------------ ------------

Total assets $ 10,175,964 $ 10,202,342
============ ============

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

CURRENT LIABILITIES:

Current portion, long term debt $ 59,414 $ 78,798

Line of Credit 1,477,140 660,200

Accounts payable 1,508,368 1,398,420

Accrued liabilities 987,286 1,590,360

Income taxes payable 37,107 39,339
------------ ------------

Total current liabilities 4,069,315 3,767,117

Long term debt less current portion 100,542 100,542
------------ ------------

Total liabilities 4,169,857 3,867,659
------------ ------------

EQUITY:

REMEDENT, INC. STOCKHOLDERS’ EQUITY

Preferred Stock $0.001 par value (10,000,000
shares authorized, none issued and
outstanding) -- --

Common stock, $0.001 par value; (50,000,000
shares authorized, 19,995,969 shares issued
and outstanding at June 30, 2009 and March
31, 2009) 19,996 19,996

Treasury stock, at cost;
723,000 at June 30, 2009 and March 31,
2009 (831,450) (831,450)

Additional paid-in capital 24,207,505 24,106,055

Accumulated deficit (17,765,460) (17,216,028)

Accumulated other comprehensive income (loss)
(foreign currency translation adjustment) (583,027) (640,595)
------------ ------------

Total Remedent, Inc. stockholders’ equity 5,047,564 5,437,978

Non-controlling interest 958,543 896,705
------------ ------------

Total stockholders’ equity 6,006,107 6,334,683
------------ ------------

Total liabilities and equity $ 10,175,964 $ 10,202,342
============ ============

REMEDENT, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

For the three months ended
June 30,

2009 2008

----------- -----------

Net sales $ 2,160,803 $ 3,635,479
Cost of sales 1,096,007 1,269,424
----------- -----------
Gross profit 1,064,796 2,366,055
----------- -----------
Operating Expenses
Research and development 26,598 124,948
Sales and marketing 350,935 671,299
General and administrative 1,042,764 1,130,313
Depreciation and amortization 173,444 91,261
----------- -----------
TOTAL OPERATING EXPENSES 1,593,741 2,017,831
----------- -----------
INCOME (LOSS) FROM OPERATIONS (528,945) 348,224
----------- -----------
OTHER INCOME (EXPENSES)
Interest expense (24,647) (35,343)
Other income 65,998 17,621
----------- -----------
TOTAL OTHER INCOME (EXPENSES) 41,351 (17,723)
----------- -----------

NET (LOSS) INCOME (487,594) 330,501

LESS: NET INCOME ATTRIBUTABLE TO THE
NON-CONTROLLING INTEREST 61,838 --
----------- -----------

NET (LOSS) INCOME ATTRIBUTABLE TO
REMEDENT, INC. Common Stockholders $ (549,432) $ 330,501
=========== ===========

INCOME (LOSS) PER SHARE
Basic $ (0.03) $ 0.02
=========== ===========
Fully diluted $ (0.03) $ 0.01
=========== ===========

WEIGHTED AVERAGE SHARES OUTSTANDING
Basic 19,995,969 18,637,803
=========== ===========
Fully diluted 32,702,274 27,000,995
=========== ===========

NET (LOSS) INCOME $ (487,594) $ 330,501

OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustment 57,568 27,592
----------- -----------

TOTAL OTHER COMPREHENSIVE (LOSS) INCOME (491,864) 358,093

LESS: COMPREHENSIVE INCOME ATTRIBUTABLE TO
NON-CONTROLLING INTEREST 42,248 --

=========== ===========

COMPREHENSIVE (LOSS) INCOME ATTRIBUTABLE TO
REMEDENT INC., Common Stockholders $ (534,112) $ 358,093
=========== ===========